Phibro Animal Health Corporation — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2021, compared primarily with fiscal years 2020 and 2019. The supplied metadata references “2020 Q4,” but the filing is an annual Form 10-K for fiscal 2021, not a quarterly filing.
Business Context
Phibro is a global animal health, mineral nutrition and specialty chemicals company. It sells more than 1,625 product presentations in over 80 countries through three segments: Animal Health, Mineral Nutrition and Performance Products. Animal Health products include medicated feed additives, nutritional specialties and vaccines for poultry, swine, cattle, dairy and aquaculture.
Manufacturing and operations continued during the COVID-19 pandemic, although the Company experienced supply-chain, logistics, employee-safety and cost pressures. Management stated that the global food and animal production industry was returning toward stability, but the duration and economic effects of the pandemic remained uncertain.
Key Financial Metrics
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Net sales | $833.4 million | $800.4 million | Up 4% |
| Gross profit | $271.4 million | $256.9 million | Up 6% |
| Gross margin | 32.6% | 32.1% | Up 50 basis points |
| Operating income | $74.9 million | $69.2 million | Up 8% |
| Net income | $54.4 million | $33.6 million | Up 62% |
| Diluted EPS | $1.34 | $0.83 | Up $0.51 |
| Adjusted EBITDA | $107.9 million | $102.1 million | Up 6% |
| Operating cash flow | $48.3 million | $59.3 million | Down $11.0 million |
| Capital expenditures | $29.3 million | $34.0 million | Down $4.7 million |
Net income benefited from higher operating income, a $5.3 million improvement in foreign-currency results and a $9.9 million reduction in income-tax expense. The effective tax rate declined to 18.2% from 39.6%; FY2021 included approximately $8.9 million of identified tax benefits, including reversals of uncertain tax positions and GILTI-related benefits. Excluding these items, management estimated an effective tax rate of approximately 31.6%.
Segment Performance
| Segment | FY2021 Sales | Change | FY2021 Adjusted EBITDA | Change |
|---|---|---|---|---|
| Animal Health | $545.7 million | Up 4% | $124.0 million | Up 1% |
| Mineral Nutrition | $220.6 million | Up 3% | $17.1 million | Up 17% |
| Performance Products | $67.1 million | Up 14% | $9.4 million | Up 108% |
- Animal Health growth was led by nutritional specialties, up 10%, and MFAs and other products, up 2%. Vaccine sales declined 3%.
- Animal Health sales in China declined $8.9 million following regulatory changes effective January 1, 2020.
- Mineral Nutrition benefited from higher average selling prices and volume growth, with pricing linked to underlying commodity costs.
- Performance Products benefited from higher volumes of copper-based products.
- Global sales of antibacterials, anticoccidials and other related products were $330.0 million, representing approximately 40% of consolidated net sales.
Liquidity, Debt and Capital Resources
- Cash and cash equivalents plus short-term investments were $93.2 million at June 30, 2021, compared with $91.3 million a year earlier.
- Working capital was $251.0 million, and the current-assets-to-current-liabilities ratio was 2.62:1.
- Total debt included $298.1 million under the Term A loan and $95.0 million under the revolving facility. Letters of credit totaled $2.7 million.
- The April 2021 refinancing established a $300.0 million Term A loan and a $250.0 million revolving facility, both maturing in April 2026. Revolver availability was approximately $152.3 million after borrowings and letters of credit.
- The Company was in compliance with its debt covenants at June 30, 2021. Interest-rate swaps effectively fixed the LIBOR component on $300.0 million of debt through June 2025.
- Financing activities used $17.0 million of cash, including $19.4 million of dividends and $2.9 million of debt issuance costs.
- Management expected available cash, operating cash flow and financing capacity to support liquidity needs for at least the next twelve months, while noting that future adequacy was not assured.
Material Changes Versus Prior Comparable Period
- Sales increased 4%, reversing the 3% decline reported in FY2020.
- Gross margin improved modestly, while SG&A increased 5% to $196.5 million because of international expansion, carbadox-related professional fees, strategic initiatives, compensation and information-technology investments.
- Operating income increased 8%, but operating cash flow declined because accounts receivable and inventory required additional cash.
- Cash used in investing activities decreased substantially to $18.6 million from $120.4 million, as FY2020 included the $54.5 million Osprey acquisition and higher short-term investment purchases.
- The Company refinanced its prior credit facilities in April 2021, extending maturity to 2026.
- Previously disclosed material weaknesses in internal control over financial reporting were reported as fully remediated as of June 30, 2021. Management and PwC concluded that internal controls were effective.
- The domestic pension plan improved from a $3.6 million liability to a $1.2 million funded position; no FY2022 contribution was expected.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide formal quantitative revenue or earnings guidance. Management highlighted long-term opportunities from global population growth, increased protein demand, resource efficiency, emerging markets, new product development, vaccine technology, microbial products and companion-animal products.
- Carbadox/Mecadox: The FDA continues to challenge the regulatory method and safety basis for carbadox. A potential withdrawal remains unresolved, with no defined timeline. FY2021 carbadox sales were $23 million.
- Antimicrobial regulation: Restrictions on medically important antimicrobials, veterinary oversight requirements, consumer concerns and possible changes to labeling could affect a material portion of sales.
- COVID-19: Future effects on customers, suppliers, manufacturing, logistics, raw-material costs and demand remain uncertain.
- Supply chain and raw materials: Commodity-price volatility, limited availability, tariffs and reliance on third-party suppliers may pressure margins and product availability.
- Regulatory and environmental matters: The Company faces extensive product-approval, manufacturing-quality, environmental remediation and permit requirements. Environmental accruals were $4.3 million at June 30, 2021, and surety bonds and letters of credit provided $12.0 million of financial assurance.
- Omega Chemical Site: Phibro-Tech is a potentially responsible party in an EPA investigation and related litigation concerning groundwater contamination. The Company stated that any ultimate liability cannot currently be predicted.
- Unusual financial items: FY2021 included a $1.0 million refinancing expense, a $4.5 million net foreign-currency gain and significant tax benefits. Adjusted EBITDA is a non-GAAP measure and should not be viewed as a substitute for GAAP net income.
- Ownership and governance: BFI Co., LLC beneficially controlled approximately 90.9% of combined voting power through the dual-class share structure.
Investor Verification Checklist
- Verify the status and potential financial impact of the FDA’s carbadox/Mecadox proceedings.
- Assess whether antimicrobial restrictions or customer preferences could reduce the Company’s approximately $330 million related product revenue base.
- Review debt covenant compliance, the April 2021 refinancing terms, maturity schedule and available revolver capacity.
- Separate recurring operating performance from FY2021 tax benefits, foreign-currency gains and refinancing costs.
- Monitor working-capital intensity, particularly inventory growth and accounts-receivable collections.
- Review environmental accruals and the unresolved Omega Chemical Site investigation and litigation.
- Evaluate the sustainability of the $0.12 quarterly dividend under debt covenants and future cash-flow requirements.
- Consider the effect of concentrated voting control, international operations, foreign exchange, regulatory approvals and COVID-19-related disruptions.